
Quarterly report 2025-Q3
added 11-04-2025
Neuronetics Net Debt 2011-2026 | STIM
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Neuronetics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -46.7 M | -58.1 M | -13.7 M | -44.6 M | -74.2 M | 409 K | 3.1 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.1 M | -74.2 M | -33.4 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
Trinity Biotech plc
TRIB
|
55.4 M | $ 0.73 | -1.86 % | $ 61.9 M | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
-76 M | $ 29.0 | -3.07 % | $ 316 M | ||
|
Brainsway Ltd.
BWAY
|
-6.88 M | $ 23.87 | -0.13 % | $ 99.4 M | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
-2.64 M | $ 1.14 | -2.16 % | $ 1.45 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | ||
|
Celcuity
CELC
|
82.8 M | $ 104.95 | -1.72 % | $ 4.14 B | ||
|
Co-Diagnostics
CODX
|
-11.9 M | - | - | $ 79.8 M | ||
|
Danaher Corporation
DHR
|
13.6 B | $ 210.56 | -0.33 % | $ 154 B | ||
|
Castle Biosciences
CSTL
|
-108 M | $ 29.41 | -6.17 % | $ 817 M | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Quest Diagnostics Incorporated
DGX
|
5.24 B | $ 202.21 | -0.11 % | $ 22.4 B | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
DexCom
DXCM
|
-842 M | $ 73.08 | 1.11 % | $ 28.5 B | ||
|
DarioHealth Corp.
DRIO
|
-12.1 M | $ 11.75 | 2.8 % | $ 333 M | ||
|
CareDx, Inc
CDNA
|
-48 M | $ 18.83 | -5.23 % | $ 1.01 B | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
Illumina
ILMN
|
-494 M | $ 117.53 | -2.06 % | $ 18.7 B | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 23.18 | -0.39 % | $ 701 M | ||
|
Exact Sciences Corporation
EXAS
|
-916 M | $ 103.45 | 0.15 % | $ 19.5 B | ||
|
Lantheus Holdings
LNTH
|
-346 M | $ 74.31 | 1.54 % | $ 5.14 B | ||
|
Guardant Health
GH
|
1.15 B | $ 103.36 | -2.84 % | $ 13 B | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 99.61 | 1.22 % | $ 8.22 B | ||
|
Interpace Biosciences
IDXG
|
105 K | $ 1.85 | 2.78 % | $ 8.12 M | ||
|
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | ||
|
Charles River Laboratories International
CRL
|
1.98 B | $ 169.68 | 3.11 % | $ 8.41 B | ||
|
IDEXX Laboratories
IDXX
|
183 M | $ 635.6 | 0.77 % | $ 52.4 B | ||
|
IQVIA Holdings
IQV
|
12 B | $ 166.19 | -1.87 % | $ 28.6 B | ||
|
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 31.19 | 0.73 % | $ 20 B | ||
|
Biodesix
BDSX
|
14.5 M | $ 13.26 | 4.0 % | $ 1.72 B | ||
|
Quidel Corporation
QDEL
|
-377 M | $ 22.47 | -4.85 % | $ 947 M | ||
|
Laboratory Corporation of America Holdings
LH
|
4 B | $ 283.38 | 0.32 % | $ 23.8 B | ||
|
Biomerica
BMRA
|
-1.94 M | $ 2.17 | -2.25 % | $ 4.98 M | ||
|
Bioventus
BVS
|
334 M | $ 8.57 | -0.06 % | $ 537 M | ||
|
Medpace Holdings
MEDP
|
-360 M | $ 452.99 | 1.47 % | $ 13.1 B | ||
|
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | ||
|
National Research Corporation
NRC
|
30.1 M | $ 13.65 | 9.64 % | $ 335 M | ||
|
Mettler-Toledo International
MTD
|
2.06 B | $ 1 378.44 | 0.14 % | $ 28.4 B |